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Semiconductor quantum dots are quickly becoming a critical diagnostic tool for discerning cellular function
at the molecular level. Their high brightness, long-lasting, size-tunable, and narrow luminescence set them
apart from conventional fluorescence dyes. Quantum dots are being developed for a variety of biologically
oriented applications, including fluorescent assays for drug discovery, disease detection, single protein
tracking, and intracellular reporting. This review introduces the science behind quantum dots and describes
how they are made biologically compatible. Several applications are also included, illustrating strategies
toward target specificity, and are followed by a discussion on the limitations of quantum dot approaches.
The article is concluded with a look at the future direction of quantum dots.Introduction
Quantum dots, nanometer-sized crystals composed of semi-
conductors, are one of the first nanotechnologies to be inte-
grated with the biological sciences. A decade after their intro-
duction to biology (Bruchez et al., 1998; Chan and Nie, 1998),
quantum dots are proven powerful probes for fluorescence
imaging and are being developed for a range of additional appli-
cations including the detection of disease, fluorescent assays for
drug discovery, single protein tracking, and intracellular report-
ing. Quantum dots have five distinct properties that give them
their unique capabilities. First, the dots themselves are small,
ranging from 4 to 12 nm in diameter. Second, they have size-
tunable, narrow, Gaussian emission spectra that can be excited
at a single wavelength, enabling multiplexed experiments. Third,
they have enormous absorption extinction coefficients and high
fluorescent quantum yields, making them exceptionally bright.
Indeed, the emission of a single quantum dot can be discerned
by eye with a fluorescent microscope. Fourth, they are inorganic
and thus photochemically robust. Their resistance to photo-
bleaching enables extended dynamic imaging. Finally, quantum
dots ‘‘blink.’’ This fluorescence intermittency assures the obser-
vation of a single dot event, which translates to the observation
of a single protein. These properties are enabling a new genera-
tion of fluorescence imaging experiments in biology allowing
investigators to unravel biological function at themolecular level.
The synthesis of highly fluorescent, monodisperse quantum
dots is sufficiently advanced that they are commercially available
(Invitrogen, Evident Technologies, Ocean NanoTech). Biocom-
patibility and biological targeting is achieved through surface
modification and conjugation with antibodies, peptides, or small
molecules. Most bioconjugation is straightforward and can be
performed in a biology lab; it does not require skilled chemists.
The would-be quantum dot user does have to take great care
to defeat, or at least minimize, nonspecific binding (NSB) as10 Chemistry & Biology 18, January 28, 2011 ª2011 Elsevier Ltd All rthis can easily lead to the misinterpretation of experimental
results. Rigorous controls are a must in quantum dot experi-
ments, and where rigorous controls are absent in the literature
the reader should be skeptical. Analytical tools are becoming
available online for the analysis of quantum dot single protein
tracking experiments, so much is at hand for the investigator
considering adding quantum dots to his or her experimental
arsenal (Serge et al., 2008; Jaqaman et al., 2008).
This review is aimed at introducing the reader to the field of
quantum dots and providing enough information in the text and
the references to encourage a new quantum dot user to get
started. We answer the question, ‘‘What is a quantum dot?’’
and describe the basic design principles for making biologically
compatible quantum dots. Several applications exploiting the
properties of quantum dots are presented, and we also discuss
some of the limitations of quantum dots. We close with
a prospectus of the future for quantum dots.
Basic Quantum Dot Design Principles
Quantum dot design comprises three components: synthesizing
the quantum dot, modifying its surface so that it is biologically
compatible, and then further modifying the surface so that the
dot can be directed to a target. There are three primary ways
to target a biocompatible quantum dot: with antibodies, with
peptides, or with small molecules.
Quantum Dot Design
What Is a Quantum Dot?
A quantum dot is a nanometer-sized crystal of inorganic semi-
conductor, or semiconductor nanocrystal (Figure 1). It has the
same arrangement of atoms as in the corresponding bulk mate-
rial, but many more surface atoms due to three-dimensional
truncation. A 2 nm crystal contains approximately 200 atoms,
whereas an 8 nm crystal would contain some 10,000 atoms.ights reserved
Figure 1. Putative Structure and Size-Dependent Absorption
and Emission Spectra of CdSe Nanocrystals
(A) Upon excitation with a photon, an electron-hole pair is created in a nano-
crystal. If the electron and hole recombine, fluorescence is given off. If the
carriers get trapped to the surface, they are lost. By coating the surface with
another semiconductor, material surface loss is eliminated.
(B) Absorption and emission spectra of a series of CdSe nanocrystals. The
CdSe core controls the spectral properties of CdSe/CdZnS fluorescent
quantum dot. As the size of the core increases, the absorption and emission
wavelengths shift to the red. However, as the absorption is continuous above
the first excitation peak, one excitation source can be used to excite all sizes of
core/shell quantum dots.
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sically have organic ligands capping some of the surface atoms.
The name ‘‘quantum dot’’ originates from the fact that the optical
properties of the nanocrystal (the ‘‘dot’’) are dictated by quantum
mechanics. Here’s how it works: when a semiconductor absorbs
a photon, an electron is promoted to the conduction band, and
a region of positive charge, called the ‘‘hole,’’ is left behind in
the valence band. The electron and hole can move around inChemistry & Biolthe bulk material, but there is the Coulomb attraction that keeps
them together, and the electron orbits the hole at some average
distance as in the Bohr model of the atom. As an example, in the
semiconductor CdSe the radius of the electron orbit in the bulk
material is56 A˚. So, if you chemically synthesize a CdSe nano-
crystal that has a radius smaller than 56 A˚, you begin to
‘‘squeeze’’ the electron and hole, and there is confinement
energy. The quantum mechanical confinement causes the
energy states to shift to higher levels, or blue shift. The smaller
you make the nanocrystal, the more you squeeze the electron
and the hole, and the higher the energy levels go. So, large
CdSe nanocrystals absorb and emit in the red, small nanocrys-
tals absorb and emit in the blue, and the wavelength of emission
can be tuned by size (Figure 1B). Changing the nanocrystal
composition will change the wavelength range over which the
optical properties can be tuned. For example switching from
CdSe to ZnSe will lead to bluer nanocrystals, whereas CdTe
nanocrystals have energy levels corresponding to near-infrared
(NIR) emission in the water window. The lowest wavelength at
which the nanocrystal will absorb and emit is dictated by the
bulk band gap of the semiconductor. The quantum mechanics
behind the size-tunable optical properties of quantum dots are
very similar to the ‘‘particle-in-a-box’’ model taught in under-
graduate chemistry and physics (Brus, 1984; Kippeny et al.,
2002). The smaller the box, the higher the energy levels, following
1/L2 where L is the length of the box.
Nanocrystal Synthesis and ‘‘Core/Shell’’ Nanocrystals
As quantum dots are commercially available, it is no longer
necessary to be a chemist or to collaborate with a chemist in
order to utilize quantum dots in biology, so we will not belabor
quantum dot synthetic methodology details here (for extensive
review, see Rosenthal et al., 2007). However, nanocrystal
synthesis dictates properties, so it is important for the end-user
to know some details. Although introduced by Brus in 1984, the
nanocrystal field did not really take off until 1993, when Murray
and Bawendi developed a synthetic methodology to make large
quantities of monodisperse nanocrystals (Brus, 1984; Murray
et al., 1993). This method uses the injection of the Cd and Se
precursors into super-hot surfactant. This nucleates small nano-
crystals; then the temperature is dropped, and the nanocrystals
are allowed to grow. The reaction is stopped when the desired
size is achieved. The separation of nucleation and growth steps
allows for maintaining a good size distribution, and much study
of the size-dependent properties of nanocrystals commenced
(Alivisatos, 1996a, 1996b). The organic surfactants in which the
nanocrystals are grown ultimately become the ligands on the
surface of the nanocrystal. Nanocrystals grown this way are
not particularly fluorescent (10% quantum yield). The problem
is that not all of the surface atoms are bound to ligands—some
of the surface atoms are bare. The dangling bonds on these
surface atoms are traps. If an electron or hole gets stuck on
a trap then they lose energy, and some cannot recombine with
each other to give off light. In 1996, Hines and Guyot-Sionnest
had a very clever idea to get around this problem: wrap the
core of one semiconductor in the shell of another before capping
it with the surface ligands (Hines and Guyot-Sionnest, 1996). If
the shell material has a wider band gap than the core material,
then energetically the electron and hole cannot get into the shell
and will have no choice but to recombine and give off light. Also,ogy 18, January 28, 2011 ª2011 Elsevier Ltd All rights reserved 11
Figure 2. Z-STEM of Quantum Dots
(A) Z-STEM image of a CdSe/ZnS core/shell nanocrystal. The intensity profile clearly indicates the interface between core and shell. The shell appears to be
growing primarily off of one facet of the core. (B) Aberration-corrected Z-STEM (Fourier filtered) image of a commercial quantum dot (QD655). The CdS shell
can be identified by the loss of the anion atomic dumbbell in the image.
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dangling bonds on the core, so trap states are eliminated.
Thus, fluorescent ‘‘core/shell’’ nanocrystals were born with fluo-
rescent quantum yields of up to 35% (Dabbousi et al., 1997).
How to Engineer a QuantumDot with a 95% Fluorescent
Quantum Yield
Although articles reporting the application of fluorescent
quantum dots started to appear (Gerion et al., 2002; Dahan
et al., 2001; Dubertret et al., 2002; Rosenthal et al., 2002), there
were still major inadequacies with the dots. First, the dots were
not particularly bright; second, conjugation strategies tended
to lower the fluorescence quantum efficiency; third, the dots
often lacked good solubility in buffer and tended to aggregate.
The first problem, low quantum yield, was solved by a collabora-
tive team of scientists fromQuantumDot Corporation, Vanderbilt
University, and Oak Ridge National Laboratory and combined12 Chemistry & Biology 18, January 28, 2011 ª2011 Elsevier Ltd All rsynthetic design with sophisticated aberration-corrected,
atomic number-contrast scanning transmission electronmicros-
copy (McBride et al., 2004). Z-STEM imaging of core/shell CdSe/
ZnS nanocrystals made then by current methods revealed that
shell growth was not uniform; there were patches of the CdSe
core that were not passivated by the shell, leading to surface
dangling bond trap states as described above, and therefore
the fluorescence quantum yield of the dots was low (Figure 2A).
The problem was similar to creating heterostructures in thin
film surface science. The lattice mismatch between CdSe and
ZnS is 14%; that is, the registry of Cd and Se atoms in the
CdSe lattice is offset from the arrangement of Zn and S atoms
in the ZnS lattice by 14%. As a result, it is difficult to put ZnS
down on CdSe, and if a layer of ZnS forms, the next Zn and S
atoms will prefer to grow on ZnS instead of CdSe. This problem
was solved by adding in some Cd atoms during the growth of theights reserved
Figure 3. Amphiphilic Polymer Encapsulation Strategy
The original nonpolar ligands on the surface of a quantum dot are left intact (A),
and an amphiphilic polymer is used to encapsulate the dot in a water-soluble
plastic bag (B). Nonpolar side chains of the polymer intercalate with the
nonpolar ligands capping the nanocrystal, and the outer polar, chemically
reactive groups of the polymer are used for further conjugation (C).
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nanocrystals had essentially perfect shell growth (Figure 2B)
and resulting fluorescent quantum yields that exceeded 95%
(McBride et al., 2006). These core/shell nanocrystals are not
simple spheres, as one might imagine, but rather have a bullet
shape, owing to preferential growth on the Se terminated facets.
These are the core/shell quantum dots that are available from
Invitrogen.
Biological Compatibility and Targeting of Quantum Dots
Introduction of Buffer Compatibility to the Quantum Dot
without Quenching
As described above, the synthesis of quantum dots results in an
organic ligand on the surface of the nanocrystal. This is true for
both simple nanocrystals and core/shell nanocrystals. These
organic capping ligands are always nonpolar, which means
that another step in the synthesis of biologically useful nano-
crystals is to make them soluble in a buffer. An original
approach to this problem was to exchange the nonpolar ligands
on the surface of the nanocrystal with polar ligands, usually
using a thiol functional group for attachment to the surface of
the nanocrystal (Chan and Nie, 1998; Pathak et al., 2001). This
was problematic. First, thiols tend to quench the fluorescence
of quantum dots, and the surface ligand-exchanged dots
were not as bright as the original quantum dots with their native,
nonpolar surface ligands. Second, the Cd-thiol bonds were not
particularly stable, which could affect quantum dot performance
over time.
Bruchez solved this problem using an amphiphilic polymer
strategy (Figure 3) (Wu et al., 2002). As the native ligands
(Figure 3A) provide for the brightest quantum dots, Bruchez left
the original nonpolar ligands intact, and, instead of exchanging
them, he used an amphiphilic polymer to essentially encapsulateChemistry & Biolthe dot in a ‘‘plastic bag’’ that was water soluble. Nonpolar side
chains on the polymer intercalate with the nonpolar ligands
capping the nanocrystal (Figure 3B), and then the polymer is
crosslinked to encapsulate the nonpolar portion, leaving polar,
chemically reactive groups on the outer surface (Figure 3C),
yielding bright dots that are soluble in buffer and have a chemical
handle for further bioconjugation (Figure 3C). These are the AMP
Dots available from Invitrogen. The encapsulated quantum dots
depicted in Figure 3 are terminated with carboxylic acid func-
tional groups, but it is possible to utilize amphiphilic polymer
strategies to arrive at dots with other terminating functionalities.
This is achieved by reacting the carboxylic acid functionalities
with crosslinking reagents. Frequently the carboxylic acid func-
tionalities on the AMP surface are reacted with diamino polyeth-
ylene glycols, resulting in quantum dots that have amino
functionalities on their surfaces. These dots may be conjugated
to proteins, peptides, and small molecules via an amide linkage.
Alternatively, the amino functionality may be modified further by
reacting it with crosslinking reagents such as SMCC (succini-
midyl 4-[N-maleimidomethyl]cyclohexane-1-carboxylate) result-
ing in quantum dots that have maleimide groups on their
surfaces. Maleimide-coated quantum dots may be conjugated
to molecules containing free thiols, such as antibodies and anti-
body fragments. The polymer coating on the core/shell nano-
crystals also increases their size; it has been reported that the
diameters of nanocrystals encapsulated in poly(maleic anhy-
dride alt-1-tetradecene) increases by 1.2 nm (Pellegrino et al.,
2004). Since this polymer has a similar structure to the modified
amphiphilic polyacrylamide polymer used to encapsulate the
AMP dots, the diameters of these dots are likely to increase by
a similar factor. Thus, it is probable that the AMP coating adds
1–2 nm to the AMP dots diameter, resulting in dots with diame-
ters in the range of 5–14 nm. We will discuss newer strategies
to obtain buffer solubility and reduce quantum dot size
below. For an extensive coverage on alternative quantum dot
manufacturing and capping strategies, refer to Medintz et al.
(2005); Peng and Peng (2000), and Qu et al. (2001).
Conjugation Chemistries to Attach a Biological
Targeting Moiety to Buffer-Compatible Quantum Dots
Various chemistries are available to conjugate biologically active
molecules to the surface of nanocrystals. Table 1 lists several
possible quantum dot-terminating functional groups, possible
terminating groups on the biologically active molecule, and the
chemical reagent that is used to link the two. For example,
EDAC (1-ethyl-3-[3-dimethylaminopropyl]carbodiimide hydro-
chloride) can be used to couple carboxylic acid-terminated
dots to biologically activemolecules containing amines, whereas
crosslinking reagents such as SMCC and N-hydroxysuccini-
midyl iodoacetate (SIA) (Orndorff and Rosenthal, 2009) can be
used to couple thiols to quantumdots with an amino functionality
on their surfaces. Peptides can be coupled to the surface of
amine terminated quantum dots using SIA and Traut’s reagent
(Orndorff et al., 2008). One very convenient, almost universal
strategy is to link streptavidin to the surface of the quantum
dot, and then use a biotinylated targeting moiety that will link
to the streptavidin. Streptavidin can be linked to the surface of
quantum dots by utilizing the reagent EDAC to crosslink carbox-
ylic acid groups on the surface of the dot with amino acid side
chains on the surface of the streptavidin (Medintz et al., 2005).ogy 18, January 28, 2011 ª2011 Elsevier Ltd All rights reserved 13
Table 1. Conjugation Strategies to Functionalize Quantum Dots
Quantum Dot  
Terminating 
Group 
Biomolecule 
Terminating 
Group 
Linking Agent 
(Full Name) 
Example 
(References) 
Carboxylic Acid Amine 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide Tomlinson et al., 2007; Gussin et al., 2006 
Amine Amine Traut’s reagent, N-hydroxysuccinimidyl iodoacetate (SIA) Orndorff and Rosenthal, 2009 
Amine Thiol Sulfosuccinimidyl 6-(3'-[2-pyridyldithio]-propionamido)hexanoate (Sulfo-LC-SPDP) Derfus et al., 2007 
nitoiBnidivatpertS/nidivA Bakalova et al., 2005; Soman and Giorgio, 2007; Tomlinson et al., 2006; Tomlinson et al., 2005 
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available. The streptavidin-biotin strategy adds substantial bulk
to the quantum dots. Streptavidin-coated quantum dots have
diameters that are of the order of 15–20 nm.
It is common to incorporate linker arms between the quantum
dot and the biological targetingmoiety to provide steric freedom.
This strategy is especially common if the targeting moiety is
a small molecule or a small peptide. The linker arm can serve
a dual purpose; for example, polyethylene glycol chains can
reduce nonspecific binding, as we will discuss below. Examples
of linker arms are given in Figure S1 (available online).
Modifying the Quantum Dot Surface to Direct It
to a Target
There are three primary means to direct a quantum dot to label
a target: antibodies, peptides, and small molecules. The
simplest labeling strategy uses antibodies; the most compli-
cated is that of small molecules, as this approach usually
requires more synthetic chemistry. Each approach has its
advantages and disadvantages, and no approach is universal
for all applications.
Antibody Targeting
If an antibody exists for an extracellular epitope of the target,
then the simplest and quickest labeling route is to use an anti-
body-quantum dot conjugate. Antibody-quantum dot conju-
gates have been used in a myriad of applications. Examples
include using antibodies for F and G proteins on two sizes of
quantum dots to detect the presence and follow the progression
of respiratory syncytial viral infection in vitro (Bentzen et al.,
2005a), using antibody-conjugated quantum dots to target
a prostate-specific membrane antigen in tumors in vivo in mice
(Gao et al., 2004), and using anti-HER2 quantum dot conjugates
to image breast cancer cells in vitro (Wu et al., 2002) and in vivo
(Tada et al., 2007). Antibodies can be biotinylated and used with
streptavidin-coated quantum dots, or they can be directly conju-
gated to the quantumdot. A simple kit requiring no prior quantum
dot experience for linking antibodies to AMP quantum dots is
commercially available from Invitrogen. This kit comprises
dithiothreitol (DTT) and an SMCC crosslinker. The DTT is used
to reduce disulphide bonds in the antibody resulting in free thiols,
and these may then be bound to the AMP surface utilizing the
SMCC crosslinker (Pathak et al., 2007). A wide selection of anti-
body-quantum dot conjugates is also commercially available.
Disadvantages to this approach include the availability of anti-
bodies, their selectivity and affinity, and the increased hydrody-
namic radius of the quantum dot conjugate. Nonetheless,14 Chemistry & Biology 18, January 28, 2011 ª2011 Elsevier Ltd All rantibody-quantumdot conjugates areoften themethodof choice
and make up much of the quantum dot-in-biology literature.
Peptide Targeting
When ligand-target interactions are facilitated by a peptide
epitope of a protein or a known peptide, it is logical to utilize
a peptide-quantumdot nanoconjugate for labeling. Similar to anti-
body recognition, the strength of peptide-target interaction is
highlyvariable.However, theuseofpeptides inquantumdotprobe
architecture leads to significant reduction of expenses associated
with synthesis and the ultimate nanoconjugate size. Additionally,
covalent conjugation of multiple peptides to one quantum dot
may considerably increase the binding capacity of the resulting
complexes to the target throughmultivalent interactions. Covalent
conjugation of peptides to quantum dots is typically achieved
through the use of water-soluble crosslinking reagents such as
EDAC, SIA, and Traut’s reagent (Orndorff et al., 2008; Orndorff
and Rosenthal, 2009). An alternative route is to utilize streptavi-
din-biotin noncovalent self-assembly (Chen and Gerion, 2004).
Peptide-functionalized quantum dots have been successfully
used for targeting cellular proteins such as growth factor recep-
tors, G protein-coupled receptors, integrins, and ion channels
(Vu et al., 2005; Tomlinson et al., 2005b; Cai et al., 2006; Orndorff
and Rosenthal, 2009). In particular, Smith et al. conjugated
30–50 arginine-glycine-aspartatic acid (RGD) peptides to NIR
quantum dots to specifically target avb3 integrins inmouse tumor
neovasculature in vivo, while Orndorff et al. relied on high-affinity
peptide neurotoxin quantum dot nanoconjugates to image
endogenous proteins in living cells and ex vivo tissue (Smith
et al., 2008a; Orndorff et al., 2008; Orndorff and Rosenthal,
2009). Additionally, protein transduction domains such as HIV
TAT, Pep-1, polyarginine, and SV40 T antigen have been linked
to quantum dots to facilitate intracellular delivery (Ruan et al.,
2007; Rozenzhak et al., 2005; Gao et al., 2004; Derfus et al.,
2004). Overall, peptide-quantum dot nanoconjugates offer
distinct advantages over antibody-mediated targeting, and their
potential as biological probes is being actively explored.
Small Molecule Targeting
Amethod that we have pioneered is the use of small molecules to
target quantum dots to cell surface receptors (Rosenthal et al.,
2002). Ligands with high affinity and selectivity can target the
quantum dot directly to the binding site of the protein of interest.
Examples are shown in Figure 4. Labeling the binding site of the
protein directly can initiate a dynamic process and enable
monitoring, for example, of receptor-mediated endocytosis.
Ligand-conjugated quantum dots also enable following theights reserved
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Figure 4. Small Molecule Ligands that Have Been Conjugated to Quantum Dots
(I) A PEGylated serotonin derivative (Rosenthal et al., 2002); (II) a muscimol derivative (Gussin et al., 2006); (III) a dopamine transporter antagonist (Tomlinson et al.,
2006); (IV) a serotonin transporter antagonist (Tomlinson et al., 2007); (V) GPI a tumor targeting ligand (Choi et al., 2010); (VI) A derivative of the NSAI D naproxen
(Byrne et al., 2007); (VII) dopamine (Clarke et al., 2006); (VIII) glutathione (Tortiglione et al., 2007).
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regulate protein expression and cell surfacemobility. Also, as the
quantum dot is tied off at the binding site of the protein, displace-
ment assays are possible. A test compound that targets the
binding site will displace the ligand-conjugated quantum dot,
enabling a fluorescence-based assay for drug discovery.
Ligand-conjugated quantum dots can also be used as probes
for allosteric modulation of the binding site. One can envision
several ligand-conjugated quantumdots, with each ligand conju-
gated to a different size (color) quantum dot, allowing a multi-
plexed fluorescent assay for drug discovery. Based on the struc-
ture of the cell surface receptor, the ligand can be tailored with
a linker arm that optimizes binding. The one major disadvantage
to the ligand-conjugated quantumdot approach, however, is that
fairly sophisticated organic chemistry is required to synthesize an
optimized ligand.
High-Affinity Fusion Tag Targeting Approaches
To expand the arsenal of tools for site-selective, specific
quantum dot labeling of cellular targets, several new approachesChemistry & Biolbased on high-affinity fusion tags have recently been reported.
A cellular target of interest is expressed with a genetically engi-
neered high-affinity fusion tag, usually a short peptide sequence
with a recognition epitope for complementary binding partner.
For instance, Ting and co-workers genetically fused a 15-amino
acid acceptor peptide (AP) to theNorC terminus of AMPA recep-
tors in hippocampal neurons (Howarth et al., 2005; Howarth and
Ting, 2008). The AP sequence was then biotinylated by biotin
ligase, followed by incubation with streptavidin-quantum dots.
In another example, Dahan and colleagues fused a decahistidine
tag to the N-terminus of type-1 interferon receptor subunit, and
quantum dot targeting was achieved through the use of tris-
nitriloacetic acid, which has a subnanomolar affinity for linear
polyhistidine motifs (Roullier et al., 2009). Other fusion tags
used in conjunction with quantum dots include CrAsH (Genin
et al., 2008) and Halotag (So et al., 2008).
Nonspecific Binding
Depending on the type of surface functional group, quantum
dots may display nonspecific cellular binding that negativelyogy 18, January 28, 2011 ª2011 Elsevier Ltd All rights reserved 15
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dots has been observed in several systems and has been attrib-
uted primarily to electrostatic interactions between quantum dot
surface groups (e.g., carboxyl) and the target cell surface (Gerion
et al., 2002; Bentzen et al., 2005b). In particular, Bentzen et al.
reported nonspecific cellular binding of carboxyl-terminated
AMP Dots in a cell type-dependent manner (Figure S2) (Bentzen
et al., 2005b). According to Warnement et al., quantum dots can
also be subject to nonspecific protein adsorption to the quantum
dot surface, specifically adsorption of a 66kDa serum protein
albumin present in standard blocking solutions (Figure S3)
(Warnement et al., 2008). Therefore, the would-be quantum
user must carefully examine selected quantum dot probes for
nonspecific interactions in the experimental system and choose
a surface functionalization approach that will ultimately result in
minimal nonspecific binding.
Since nonspecific cellular binding of quantumdots has a nega-
tive impact on the experiment, several approaches to address
the issue of nonspecific binding have been reported. In 2003,
Ballou et al. reported that quantum dots conjugated to
methoxy-terminated PEG5000 (molecular wt 5000 g) displayed
considerably reduced nonspecific binding in mouse animal
models (Ballou et al., 2003). In 2005, Bentzen et al. demonstrated
that a small number of methoxy PEG2000 conjugated to the
surface of AMP Dots resulted in greatly reduced nonspecific
binding in six different mammalian cell lines (Figure S2) (Bentzen
et al., 2005b). As a consequence, quantum dot PEGylation
currently constitutes the most popular approach to combat the
issue of nonspecific cellular binding. In an alternative approach,
Kairdolf et al. used 1,3-diamino-2-propanol (DAP) to facilitate
conversion of carboxylated quantum dots (coated with poly
[acrylic acid] octylamine) to hydroxylated and crosslinked dots
(Kairdolf et al., 2008). As a result, hydroxylated quantum dots
displayed a dramatic 140-fold reduction in nonspecific cellular
binding compared with that of carboxylated dots.
To sum up, nonspecific cellular binding of quantum dots is
a limiting factor in a range of biological applications, such as
live cell imaging, tissue staining, and in vivo studies. Therefore,
the would-be quantum dot user must show great care in defeat-
ing the issue of nonspecific binding and be skeptical of data that
are presented without rigorous control experiments.
Applications of Quantum Dots in Biology
The utility of quantum dots has been demonstrated in a variety of
biological and clinical applications, such as immunohistochem-
ical detection, drug delivery and therapeutics, biosensing, small
animal imaging, and single-quantum dot tracking of extra- and
intracellular targets (Medintz et al., 2008; Delehanty et al.,
2009; Medintz and Mattoussi, 2009; Gao et al., 2004; Pinaud
et al., 2010). This review focuses on examples of how quantum
dots are being used to unravel biological function at the molec-
ular level, especially in the field of neurobiology. Particular
emphasis is placed on the use of individual quantum dots to
investigatemembrane dynamics of cell surface proteins involved
in cellular signaling.
Systems aimed at detecting proteins at single-molecule level
have been a long-term desire for biologists to understand the
molecular mechanisms of protein binding, signaling, and regula-
tion. Using bright and stable quantum dots as a fluorescent tag16 Chemistry & Biology 18, January 28, 2011 ª2011 Elsevier Ltd All rfor single protein tracking is a revolutionary and exciting tool in
recent life science research (Giepmans et al., 2005; Michalet
et al., 2005; Pons and Mattoussi, 2009; Pinaud et al., 2010).
The approach to single protein tracking using quantum dots
can be divided into three steps: (1) time-series fluorescent
imaging; (2) trajectory construction; and (3) data analysis
(Figure 5). In single protein tracking, target proteins of interest
are labeled with a quantum dot in a very dilute fashion to avoid
interparticle reactions. The movement of individual target
proteins is monitored over time from an optical fluorescent
microscope system (Figure 5A). Before generating the trajectory
of each protein, subpixel location estimation from digital signals
is essential for improving the accuracy of 2D position of single
quantum dots in each frame. This is generally accomplished by
fitting the individual spot intensity values into two-dimensional
Gaussian distributions (Figure 5B). According to Pinaud et al.,
the quantum dot localization accuracy can be as low as 10 nm
with 10 ms integration time (2010). When trajectory construction
is complete, the dynamic properties of the target proteins can
then be derived through various statistical analyses of the trajec-
tories (Figure 5C). Dynamic properties (i.e., displacement,
velocity, and diffusion coefficient) provide direct access to the
influence of the intracellular microstructure or extracellular stim-
ulus on the movement of the target protein.
In 2003, Dahan and colleagues performed the first single
protein tracking experiment based on quantum dot probes
(Dahan et al., 2003). In brief, the authors tracked the lateral diffu-
sion of individual glycine receptors with antibody-conjugated
quantum dots in living neuronal cells by time-series fluorescent
microscopy. Their experiment revealed that diffusion dynamics
of glycine receptors varies in synaptic, perisynaptic, and extrasy-
naptic domain of spinal neurons. Using a similar tracking
strategy in a different study, the same group elegantly demon-
strated that the molecular mechanisms of GABAA receptors
respond to the chemotactic signaling in neurons (Bouzigues
et al., 2007). In the presence of an extracellular GABA gradient,
the authors showed that single quantum dot-labeled GABAA
receptors redistribute asymmetrically across the growth cone
(GC), located at the axon tip, toward the gradient source in
a microtubule- and calcium-dependent manner (Figure S4).
A similar concept was applied by Chu and colleagues to inves-
tigate the retrograde axonal transport of nerve growth factor
(NGF) signals (Cui et al., 2007). The authors labeled the biotiny-
lated NGF with streptavidin-conjugated quantum dots and
used total-internal-reflection fluorescence (TIRF) microscopy to
track the movement of NGF in live DRG neurons in real time.
Their experiment revealed that quantum dot-labeled NGF ex-
hibited ‘‘stop-and-go,’’ unidirectional retrograde motion within
the axons with an average speed of 1.31 ± 0.03 mm/s (Figure S5).
Another example of how quantum dots may provide valuable
insights into the molecular details of complex biological
processes is the visualization of the initial stages of receptor
tyrosine kinase-dependent signaling (Lidke et al., 2004). In his
extensive review in 2000, Schlessinger discussed the signifi-
cance of transmembrane receptor tyrosine kinases (RTKs) in
cellular signal transduction and the sheer complexity of the
signaling networks associated with RTKs (Schlessinger, 2000).
Since RTKs play a critical role in the development and prolifera-
tion of many types of cancer, Schlessinger emphasized the needights reserved
Figure 5. Approach to Single Protein Tracking Using Quantum Dots
(A) Time-lapse images of single quantum dot tagged proteins in living cells are acquired from an optical fluorescent microscope system (e.g., epifluorescence,
confocal, or total internal reflection fluorescence [TIRF] microscope).
(B) Estimation of the positions of single quantum dots with subpixel accuracy is accomplished by fitting the individual spot intensity values into a two-dimensional
Gaussian distribution. After the positions of single quantum dots are identified, trajectory of target protein (gray line) can be subsequently derived from the time-
series imaging data.
(C) The final aspect of single protein tracking is to analyze the single-quantum dot trajectories. Motion properties (i.e., displacement, velocity, and diffusion coef-
ficient) of the target proteins can then be characterized to understand how themotion dynamics of the target protein is associatedwith intracellularmicrostructure
or extracellular stimulus.
Chemistry & Biology
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logical inquiry into signaling networks associated with RTKs. It
turned out that quantum dots might be just the tool needed for
understanding the intricacies of cellular signaling.
In 2004, Lidke and co-workers used epidermal growth factor-
conjugated quantum dots to target erbB1 receptor, a member of
the RTK family of erbB proteins often dysregulated in cancerChemistry & Biol(Yarden and Sliwkowski, 2001; Lidke et al., 2004). As a result,
they discovered a previously unreported mechanism of retro-
grade transport of the receptor-quantum dot complexes from
the filopodia to the cell body in human epidermoid carcinoma
cells. Furthermore, Lidke and co-workers revealed the protein-
protein interactions (heterodimerization) between quantum dot-
bound erbB1 and erbB2 receptors and, consequently, the activeogy 18, January 28, 2011 ª2011 Elsevier Ltd All rights reserved 17
Table 2. Calculated Quantum Dot Molecular Weight
3885213116355632441144900InAs/ZnSe
3885273217258672351204635CdTe/CdS
1011571368232674152460
3544873016355631911334585
12201530713801281475356157640CdSe/ZnS
Cysteine + 
Core/Shell 
(kDa)
AMP + 
Core/shell 
(kDa)
Cysteine 
(kDa)
AMP*
(kDa)
MUA
(kDa)
DDPA 
(kDa)
Shell 
Molecular 
Weight 
(kDa)
Core 
Molecular 
Weight 
(kDa)
Core 
Diameter 
(nm)
Band Edge 
Absorption 
(nm)
Inorganic 
Core/Shell
Molecular weights were determined assuming spherical structures with 100 % ligand coverage and 2 nm of shell coverage. The ligands chosen were
dodecylphosphonic acid (DDPA), mercaptoundecanoic acid (MUA), an amphiphilic polymer-poly(maleic anhydride alt-1-tetradecene) (AMP), and
cysteine. For reference, streptavidin has a molecular weight of 52.8 kDa and GFP has a molecular weight of 26.9 kDa.
aThe AMP molecular weight was calculated as the sum of the DDPA and AMP ligands, assuming a one to one ratio of AMP and DDPA.
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Reviewrole erbB2 receptor plays in conferring higher aggressiveness to
breast cancer. This was the first successful attempt of visualizing
the erbB signaling network at the molecular level in living cells in
real time.
While quantum dots have been utilized to investigate the diffu-
sion dynamics of individualmembrane-associated proteins, their
use in small, crowded cellular locations such as neuronal
synaptic clefts (10–50 nm) has been limited by the relatively large
size and suboptimal biocompatibility (De Koninck et al., 2007).
However, with the introduction of amphiphilic polymers as
surface-passivating agents, it became possible to decrease
the size of quantum dots while simultaneously improving their
colloidal stability and mitigating nonspecific binding (Wu et al.,
2002). In 2008, Heine and co-workers used streptavidin-conju-
gated quantum dots in conjunction with a biotinylated antibody
to visualize intrasynaptic lateral mobility of AMPA glutamate
receptors (Heine et al., 2008). This report illustrated the bright
future of quantumdots as probes of first choice to study synaptic
neurotransmission at the molecular level.
Why is so much attention focused on neuronal synapses? A
synapse is the junction between two adjacent neurons that
permits the propagation of electrical or chemical signals, and
proper synaptic transmission is critical for all neuronal functions,
including movement, sensation, learning, and memory (Eccles,
1964). Signal transmission in chemical synapses is facilitated
by vesicular secretion of neurotransmitters (Eccles, 1964).
Synaptic vesicles may release their contents into the synapse
via either full-collapse fusion (FCF) or transient fusion and
retrieval, also known as Kiss-and-Run (K&R) (Smith et al.,
2008b; An and Zenisek, 2004). The preferred vesicular fusion
mode has been the subject of ongoing controversy since the
1970s (Smith et al., 2008b; An and Zenisek, 2004). In the most
remarkable display of the utility of quantum dots to under-
standing neurotransmission to date, Zhang and co-workers
loaded amphiphilic polymer-coated quantum dots into synaptic
vesicular lumen (24 nm) and successfully visualized and iden-
tified FCF and K&R fusion modes of single quantum dot-loaded
synaptic vesicles (Zhang et al., 2009). Individual vesicle imaging
was facilitated by the small size of quantum dots (15.0 ± 0.5 nm),
pH dependency of quantum dot photoluminescence (reversible
15% difference between intravesicular (pH 5.48) and extracel-
lular environment (pH 7.34)), and excellent photostability. Zhang18 Chemistry & Biology 18, January 28, 2011 ª2011 Elsevier Ltd All rand co-workers discovered that K&R and FCF can each be the
preferred fusion mode dependent on the type of stimulus
applied. K&R was found to be the predominant fusion mode
for readily releasable pool of synaptic vesicles upon rapid stim-
ulation. In addition, the duration of fusion pore opening, which
allows complete release of neurotransmitters, was determined
to be 0.5–1 s long.
In addition to specific labeling of individual cell surface biomol-
ecules, quantum dots have also been used to target intracellular
single biomolecules, such as mRNA and molecular motors
(Courty et al., 2006; Peirobon et al., 2009; Ishihama and Funatsu,
2009). However, several challenges must be overcome before
single-quantum dot tracking can be employed to probe the
dynamics of endogenous molecules inside live cells. First, it is
difficult for quantum dots to cross the plasma membrane due
to the critical effects of size, charge, and surface coating (for
intracellular delivery strategies, see Delehanty et al., 2009).
Second, once internalized, quantum dots are prone to endoso-
mal entrapment and aggregation in the acidic lysosomal environ-
ment, resulting in nonspecifically bound quantum dot probes
that cannot be easily washed away. Third, specific targeting of
endogenous intracellular molecules without in vitro preconjuga-
tion and genetic manipulation remains an important technical
challenge (Pinaud et al., 2010).
Limitations of Quantum Dots as Biological Probes
and Possible Solutions
Probe Size
While quantum dots are intrinsically small (large, red-emitting,
as-synthesized CdSe/CdZnS core/shell nanocrystals are less
than 14 nm in diameter with their native organic coating), their
size can grow substantially after being made buffer-compatible
with an AMP strategy, attaching streptavidin and an antibody,
or by using a long polyethelene glycol linker arm to attach small
molecules. Quantum dots containing heavy metals also have
substantial mass. The diameter and approximate molecular
weight of various quantum dot constructs is tabulated in Table 2.
There are several reasons to push for a smaller probe size.
Perhaps the most pressing is the desire to use quantum dots
in vivo in humans in the future. Many investigators have per-
formed studies that point to the utility of quantum dots for
in vivo use as diagnostics and therapeutics (for reviews, seeights reserved
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ReviewNie et al. [2007], Jin and Ye [2007], and Medintz et al. [2008]). In
2004, Nie and coworkers demonstrated both passive and active
targeting of quantum dots to image prostate cancer tumors in
mice (Gao et al., 2004). Waggoner, Bruchez, and co-workers
also demonstrated the capability to image quantum dots
in vivo inmice and found that the surface coating on the quantum
dot dictated where the quantum dots localized (Ballou et al.,
2003). In that same year, Frangioni and co-workers demon-
strated using large animals that NIR-emitting quantum dots
enabled a type of cancer surgery, sentinel lymph node mapping,
using image guidance provided by the quantum dots (Kim et al.,
2004). This group has also found that the biodistribution and
elimination routes of quantum dots depend on their size (Choi
et al., 2009). Recently, Kim and coworkers showed that
hyaluronic acid-functionalized quantum dots could be used to
visualize lymphatic vessels in vivo in small animals, demon-
strating the potential toward imaging the real-time development
of lymphatic vessels around tumor mass such as in lymphangio-
genesis (Bhang et al., 2009).
If quantum dots, especially those containing heavymetals, are
going to be used in in vivo applications such as diagnostic
imaging, they must clear the body. Frangioni, Bawendi, and
co-workers determined the conditions for renal filtration and
urinary excretion of quantum dots by systematically varying their
size and surface charge and have arrived at a set of design
parameters for targeted nanocrystals that can be eliminated
through the kidneys (Soo Choi et al., 2007; Choi et al., 2009). A
hydrodynamic diameter of less than 5.5 nm is the benchmark
for efficient elimination of quantum dots from the body. The
surface chemistry of the quantum dots is important to prevent
the adsorption of serum proteins, which increase the hydrody-
namic diameter of the quantum dot. Zwitterionic and neutral
organic coatings have been shown to prevent the adsorption
of serum proteins (Soo Choi et al., 2007).
A second reason to reduce the hydrodynamic radius of the
nanocrystal and its mass pertains to their use for in vitro exper-
iments. For example, the synaptic gap can be as narrow as
10 nm across. If one would like to label both presynaptic neuro-
transmitter transporters and post synaptic receptors at the
synapse in a multiplexed experiment, the quantum dots will
have to be compact. Also, for single protein tracking experi-
ments in which one is trying to elucidate the velocities of the
protein, one would not like the mass of the quantum dot label
to alter the intrinsic dynamics. Finally, quantum dots will have
to be small to study intracellular compartmentalization.
Several groups are developing synthetic strategies for
compact, fluorescent quantum dots (Choi et al., 2009; Law
et al., 2009; Perrault et al., 2009; Tromsdorf et al., 2009). The
challenge in designing quantum dots with small hydrodynamic
diameter is to maintain high quantum yields and photostability
while keeping the shell and organic coatings at a minimum.
One solution to minimize the core/shell diameter is to integrate
the shell into the core nanocrystal via alloying. Photostability
with water solubility will likely require short bidentate ligands
with carboxylic head groups, such as dihydrolipoic acid (Zimmer
et al., 2006). Liu et al. synthesized quantum dots with a hydrody-
namic diameter less than 5.5 nm which clear the renal system,
utilizing ultrasmall CdSe/ZnxCd1-xS nanocrystals capped with
cysteine, a small zwitterionic molecule (Liu et al., 2007). TheChemistry & Biolquality of the alloy shell helps minimize the reduction in fluores-
cence quantum yield when the quantum dots are transferred to
water. An alternative way to prepare smaller quantum dots is
to use semiconductor materials other than CdSe-ZnS, such as
CdTe, InP, and InAs (Smith and Nie, 2008; Xie et al., 2007;
Zimmer et al., 2006).
Multivalency
The large surface area to volume ratio of a water-soluble,
biocompatible quantum dot enables conjugation of multiple
copies of various biomolecules, such as proteins, peptides,
DNA, and small molecules. For instance, commercial streptavi-
din-quantum dot conjugates have five to ten streptavidin mole-
cules per quantum dot (Jaiswal and Simon, 2004). Such multiva-
lency effect is considered to be another distinct limitation of
quantum dots as biological probes and can be a concern in
single-quantum dot tracking experiments, where multivalent
interactions of a quantum dot with a target cell surface protein
can lead to protein crosslinking and consequently activate
signaling pathways as well as significantly impair surface protein
mobility (Saxton and Jacobson, 2003). Another undesirable
outcome of quantum dot multivalency may be increased cyto-
toxicity of the multivalent quantum dot conjugates. Recently,
Wang et al. (2010) demonstrated that cytotoxicity of PRINT
nanoparticles conjugated to nontoxic transferrin and transferrin
receptor (TfR) antibody was a function of surface ligand density.
Trf-targeted PRINT nanoparticles activated apoptopic pathways
upon receptor-mediated internalization in Ramos lymphoma
cells in a ligand density-dependent manner (Wang et al., 2010).
To date, several approaches to address quantum dot multiva-
lency have been reported; however, it has been problematic to
obtain quantum dots with exactly one surface targeting group
until Howarth et al. generated monovalent quantum dots in
2008 (Sung et al., 2004; Le´vy et al., 2006; Fu et al., 2004; Howarth
et al., 2006, 2008; Howarth and Ting, 2008). In their report,
CdSe-ZnCdS core-shell quantum dots were conjugated to
a single copy of monovalent streptavidin or antibody to carci-
noembryonic antigen. The quantum dot conjugates were
analyzed by electrophoresis in agarose gel, and a striking elec-
trophoretic mobility of quantumdots was used to purify monova-
lent conjugates. As a result, monovalency resulted in a reduced
hydrodynamic radius of the quantum dot conjugates and conse-
quently improved access to synaptic cleft as well potential
prevention of cell surface receptor complex activation.
While quantum dot multivalency is a disadvantage for imaging
protein dynamics at the single-molecule level, it can be exploited
to produce quantum dot drug carriers and imaging agents with
higher avidity for the target cells of interest as well as highly
sensitive quantum dot-based diagnostics and biosensors. In
parallel, many effective antiinflammatory and antiviral agents
are based on themultivalent drug design to amplify their potency
(Mammen et al., 1998). However, current lack of control over the
number of surface ligands and their exact orientation and confor-
mation is a significant obstacle that must be overcome to fully
harness the advantages associated with quantum dot multiva-
lency.
Blinking
Another characteristic property of quantum dots that poses
significant challenge to monitoring protein dynamics at the
single-molecule level is the photoluminescence intermittencyogy 18, January 28, 2011 ª2011 Elsevier Ltd All rights reserved 19
Chemistry & Biology
Reviewexhibited by single nanocrystals, known as blinking (Nirmal et al.,
1996; Kuno, et al., 2001). The photoluminescence spectra of
single quantum dots are characterized by large intensity fluctua-
tions, leading to the appearance of ‘‘on’’ and ‘‘off’’ states. A
single nanocrystal spends a significant fraction of time in the
‘‘off’’ or ‘‘dark’’ state even under continuous illumination, with
values as high as 100 s for commercially available avidin-conju-
gated quantum dots (Kagan et al., 1996). As a result, it can
become difficult to establish correspondence between consec-
utive frames of the time-lapse image sequence for blinking
quantum dots in tracking applications (Bannai et al., 2007). On
the other hand, the advantage of blinking is that it can be used
as a criterion for distinguishing single quantum dots from aggre-
gates ((Nirmal et al., 1996; Kuno, et al., 2001).
Despite extensive interrogation over the last decade, funda-
mental processes responsible for photoluminescence intermit-
tency of quantumdots have not been fully understood. Currently,
blinking is believed to be primarily caused by long-lived extra
charges residing in deep-trap energy states at the nanocrystal
surface, thereby enhancing the rate of nonradiative recombina-
tion processes (Efros and Rosen, 1997; Frantsuzov et al.,
2008; Kuno et al., 2001, Shimizu et al., 2001). It has been demon-
strated that surface-bound ligands (Hohng and Ha, 2004; Fo-
menko and Nesbitt, 2007) and thicker shells (Chen et al., 2008;
Mahler et al., 2008) significantly reduce blinking, albeit not
completely, by eliminating deep-trap surface states. In a recent
effort to achieve complete blinking suppression, Wang et al.
(2009) synthesized continuously emitting alloyed CdZnSe-
ZnSe core-shell nanocrystals. Although the use of such non-
blinking quantum dots makes for easier fluorescence detection
and identification, the broad multipeaked photoluminescence
spectra of CdZnSe-ZnSe quantum dots make them unsuitable
for a multicolor experiment that involves simultaneous moni-
toring of several fluorophores.
Sensors
Although the utility of quantum dots in unraveling biological func-
tion at the molecular level has been successfully demonstrated,
their potential for biosensing applications has largely been
untapped. Owing to their unique spectral properties and physi-
cochemical stability, it is apparent that quantum dots effectively
address some of the limitations encountered by conventional flu-
orophores currently forming the basis for biosensors and bioa-
nalytical assays, yet quantum dot use in biosensing applications
has thus far been limited to proof-of-concept experiments.
Recent advances in adapting quantum dots for predominantly
in vitro biosensing applications, such as immunoassays, nucleic
acid detection, and fluorescence resonance energy transfer
(FRET)-based sensing have been extensively described (Saps-
ford et al., 2006; Medintz and Mattoussi, 2009). Here, we focus
on the limitations that have precluded quantum dots from finding
widespread use in biosensing applications.
Multivalency, as discussed above, renders quantum dots an
attractive nanoscaffold that can accommodate multiple copies
of different functional elements. Not only can such architecture
result in higher sensitivity and lower limits of detection, but it
may also serve as a basis for multifunctional biosensors.
However, as previously mentioned, it is current lack of control
over conjugation stoichiometry as well as the orientation and
conformation of a surface sensing element that is a major20 Chemistry & Biology 18, January 28, 2011 ª2011 Elsevier Ltd All robstacle to fully capturing the advantages of multivalency.
Failure to determine the exact number and orientation in space
of a surface sensing element in a reproducible manner can
lead to either under- or overestimation of an analyte-specific
signal. This is particularly relevant in the case of ligand-binding
assays, where the number and conformation of ligand-specific
proteins present at the surface of a quantum dot are critical to
accurate determination of ligand potency.
Compared with conventional fluorophores, quantum dots are
characterized by larger size, which enables multivalency and
may be useful in ex vivo sensing applications. However, their
relatively large size becomes a significant concern for in vivo
sensing applications and FRET-based biosensing. Since the
issue of quantum dot renal clearance in in vivo applications
has been discussed above, importance of quantum dot size in
FRET-based biosensing is considered here. In a FRET-based
sensor, Fo¨rster or fluorescence resonance energy transfer effi-
ciency between a donor-acceptor (D-A) pair of fluorophores is
measured to monitor such biological events as ligand-receptor
binding, protein-protein interactions, and conformational
changes (Selvin, 2000; Sekar and Periasamy, 2003). Highly effi-
cient FRET requires short D-A separation distances (1–10 nm).
The final size of a water-soluble, functionalized quantum dot
poses a serious limitation, often exceeding the donor-acceptor
distance required for efficient FRET. Nevertheless, as a result
of their high quantum yield, superior physicochemical stability,
and size-tunable, narrow photoluminescence spectra, quantum
dots have been used in a number of FRET-based sensors,
predominantly as a donor molecule. For instance, Medintz
et al. used a quantum dot-Cy3 FRET pair to detect the maltose
sugar in solution in a dose-dependent manner (Medintz et al.,
2006). In their design, positively charged, Cy3-labeled maltose-
binding proteins (MBP) were prebound with a maltose analog-
Cy3.5 dark quencher and then self-assembled on the surface
of dihydrolipoic acid (DHLA)-capped quantum dots. Upon
quantum dot excitation, FRET photoluminescence of Cy3
was fully quenched by the Cy3.5 dark quencher in a control
solution, whereas addition of maltose resulted in the displace-
ment of the maltose analog-dark quencher complex and conse-
quent Cy3 photoluminescence recovery. In another example,
Zhang et al. constructed a single quantum dot-FRET biosensor
for accurate and sensitive DNA detection in solution (Zhang
et al., 2005). The Cy-5-labeled target DNA sequence was
detected by hybridization with the biotinylated complementary
DNA strand, and the resulting Cy5-labeled DNA complex was
captured with streptavidin-conjugated quantum dots in a highly
sensitive manner.
To date, quantum dots have been predominantly utilized as
donor molecules in FRET-based sensing assays. Their use as
FRET acceptors has been limited by two key properties. First,
although their broad absorption profile presents a distinct
advantage in multiplexed experiments, it results in unavoidable
direct excitation. Second, it has been reported that the lifetime
of the acceptor relative to that of the donor is critical to efficient
FRET. Quantum dots have a longer excited-state lifetime
compared to that of organic dyes, and it has been shown that
FRET is virtually absent in dye-quantum dot D-A pairs even at
favorable separation distances (Clapp et al., 2005; Clapp et al.,
2006).ights reserved
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chemistry and conjugation strategies, surface modification and
functionalization remains the most important issue when utilizing
quantum dots as a basis for biosensing applications. A single
surface modification step may require several purification steps,
often resulting in unwanted aggregation andcrosslinking (Jaiswal
and Simon, 2004). Nevertheless, quantum dots have come a
long way since their introduction to the field and have a large
potential in biosensing applications that still remains untapped.
Future Outlook
Quantum dots will become, and one can argue they already are,
and indispensable tool for biological research. Quantum dots will
see increasing use to elucidate the molecular mechanisms of
protein binding, signaling, and regulation. They will be used to
establish molecular mechanisms of disease and at the same
time become a tool for drug discovery to treat disease. In the
future we may also see further incorporation of quantum dots
as cell reporters of biological function, implementation as
tools for interrogating tissue, and forming the basis of novel
biochemical assays. The varieties of commercially available
quantum dots for the research community will continue to
grow and dual-functional nanoparticles will become available,
such as particles that can be used for dual imaging modalites.
We believe that the future of quantum dots in biology is as bright
as the quantum dots themselves.
SUPPLEMENTAL INFORMATION
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